GILD is up 1.70% today. Volume is 6.04M vs a 30-day average of 6.03M (1.00x).
Gilead Sciences, Inc. is scheduled to report earnings Thu, Oct 29, 2026 · after close. Analysts expect EPS of $2.24 on revenue of about $7.96B. Stocks often move sharply on earnings day.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential per…
Gilead Sciences (GILD) is back in focus after outlining new data it plans to showcase at The Liver Meeting 2026 on its liver disease drugs Livdelzi and Hepcludex, drawing fresh at…
Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on GIL…
FOSTER CITY, Calif., October 22, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor pro…
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, f…